Gerd Fatkenheuer
Expertise in
9
conditions

Gerd Fatkenheuer

Kerpener Str. 62, 
Koeln, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
Kerpener Str. 62, 
Koeln, NW, DE 

Overview

Gerd Fatkenheuer practices practicing medicine in Koeln, Germany.

Mr. Fatkenheuer is highly rated in 9 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), Asymptomatic Bacteriuria, and Disseminated Tuberculosis.

He is actively involved in clinical research, co-authoring 226 peer reviewed articles and participating in 9 clinical trials.

Gender

Male

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)
Study on Pharmacokinetics of Newly Developed ANtiretroviral Agents in HIV-infected pregNAnt Women (PANNA)
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Microbiome-based Stratification of Individuals at Risk of HIV-1 Acquisition, Chronic Clinical Complications, Antimicrobial Drug Resistance, and Unresponsiveness to Therapeutic HIV-1 Vaccination
Microbiome-based Stratification of Individuals at Risk of HIV-1 Acquisition, Chronic Clinical Complications, Antimicrobial Drug Resistance, and Unresponsiveness to Therapeutic HIV-1 Vaccination
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Enrollment Status: Terminated
Publish Date: October 03, 2024
Intervention Type: Drug, Biological
Study Drug: DZIF-10c Vaccine
Study Phase: Phase 1/Phase 2
A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Biological
Study Drug: DZIF-10c Vaccine
Study Phase: Phase 1/Phase 2
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection
Enrollment Status: Completed
Publish Date: May 27, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
Enrollment Status: Completed
Publish Date: November 01, 2019
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 7 Less Clinical Trials

226 Total Publications

Prevention of infectious diseases : The role of infectious disease specialists
Prevention of infectious diseases : The role of infectious disease specialists
Journal: Innere Medizin (Heidelberg, Germany)
Published: February 11, 2026

Frequently Asked Questions about Gerd Fatkenheuer

Is Gerd Fatkenheuer a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Gerd Fatkenheuer is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gerd Fatkenheuer participate in research or clinical trials?

Yes. Gerd Fatkenheuer has published 226 articles and abstracts on conditions like HIV/AIDS. You can view a list of Gerd Fatkenheuer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Fatkenheuer's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile